SK Biopharmaceuticals Co., Ltd. (KRX:326030)

Market Cap	6.22T -27.5%
Revenue (ttm)	861.34B +38.9%
Net Income	400.96B +56.6%
EPS	5,119.90 +56.6%
Shares Out	78.31M
PE Ratio	15.51
Forward PE	16.80
Dividend	n/a
Ex-Dividend Date	n/a

Volume	175,039
Open	79,400
Previous Close	83,400
Day's Range	77,200 - 80,200
52-Week Range	73,000 - 144,100
Beta	0.74
Analysts	Buy
Price Target	130,333.33 (+64.15%)
Earnings Date	Nov 6, 2026

About SK Biopharmaceuticals

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilep...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 246
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 326030

Financial Performance

In 2025, SK Biopharmaceuticals's revenue was 706.74 billion, an increase of 29.06% compared to the previous year's 547.60 billion. Earnings were 266.95 billion, an increase of 10.89%.

Analyst Summary

According to 12 analysts, the average rating for 326030 stock is "Buy." The 12-month stock price target is ₩130,333, which is an increase of 64.15% from the latest price.

Price Target

₩130,333

(64.15% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error